预约演示

Immutep to Participate in September Investor Conferences

2023-09-05

免疫疗法

SYDNEY, AUSTRALIA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will participate in the following upcoming investor conferences in September:

The 18th Annual Citi Biopharma Conference in Boston, MA on Thursday, September 7.

Bell Potter Emerging Ideas Leaders Conference on Tuesday, September 12. Presentation at 3:30 p.m. AEST.

Baird 2023 Global Healthcare Conference in New York City, NY on Tuesday, September 12. Fireside chat at 3:45 p.m. ET.

E&P Small Caps Conference on Wednesday, September 13. Presentation 3:50 p.m. AEST.

2023 Cantor Global Healthcare Conference in New York City, NY on Tuesday, September 26. Panel presentation at 2:45 p.m. ET.

Further information about upcoming conferences and events that management will be attending is available at the Events page within the Investors & Media section of Immutep’s website.

About Immutep

Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Chris Basta, VP, Investor Relations and Corporate Communications

+1 (631) 318 4000; chris.basta@immutep.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构